# VYVGART (efgartigimod) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/efgartigimod

> The PDUFA target action date for VYVGART (efgartigimod), sponsored by ARGENX SE (ARGX), is Feb 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VYVGART (efgartigimod) |
| Codes | ARGX-113 |
| Sponsor | ARGENX SE (ARGX) https://sec-api.dev/companies/argx/catalysts |
| Indications | [gmg](https://sec-api.dev/indications/gmg), achr-antibody-positive mg, [autoimmune myositis](https://sec-api.dev/indications/autoimmune-myositis), [myasthenia gravis](https://sec-api.dev/indications/myasthenia-gravis), with seronegative gmg, [Primary Immune Thrombocytopenia](https://sec-api.dev/indications/primary-immune-thrombocytopenia) |
| Modality |  |
| FDA designations | fast track |

## Timeline

### March 22, 2022: topline data readout

- Status: completed, met. Date confidence: exact. Stage: 3. Indication: gMG.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "On March 22, 2022, we announced positive topline results from the Phase 3 ADAPT-SC clinical trial, a registrational non-inferiority bridging clinical trial of efgartigimod SC for the treatment of gMG. efgartigimod SC achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical noninferiority to VYVGART IV formulation in gMG patients." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- SEC Form 10-K (accession 0001697862-25-000024): "On March 22, 2022, we announced positive topline results from the Phase 3 ADAPT-SC clinical trial, a registrational non-inferiority bridging clinical trial of efgartigimod SC for the treatment of gMG. efgartigimod SC achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical noninferiority to VYVGART" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000024/argx-20241231.htm

### June 21, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "For instance, in 2024, we announced the FDA approval of VYVGART HYTRULO for CIDP on June 21, 2024, which positively influenced the stock price between June 15, 2024 and July 1, 2024." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm

### April 10, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-04-11, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-033857): "SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) approved a new option for patients to self-inject VYVGART®" https://www.sec.gov/Archives/edgar/data/1697862/000110465925033857/tm2511923d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001159036-25-000033): "•In April 2025, argenx received FDA approval of VYVGART® Hytrulo prefilled syringe for self-injection for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive and adult patients with CIDP." https://www.sec.gov/Archives/edgar/data/1159036/000115903625000033/ex991q220258-k.htm
- Press release filed with the SEC (EX-99) (accession 0001159036-25-000025): "•In April 2025, argenx received U.S. Food and Drug Administration ("FDA") approval of VYVGART® Hytrulo prefilled syringe for self-injection for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive and adult patients with CIDP." https://www.sec.gov/Archives/edgar/data/1159036/000115903625000025/ex991q120258-k.htm
- SEC Form 10-Q (accession 0001628280-25-038548): "•Efgartigimod (FcRn): In April 2025, our partner argenx announced that the FDA had approved VYVGART Hytrulo prefilled syringe ("PFS") for self-injection in gMG and CIDP." https://www.sec.gov/Archives/edgar/data/1704292/000162828025038548/zlab-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-023411): "•Efgartigimod (FcRn): In April 2025, our partner argenx announced that the FDA had approved VYVGART Hytrulo prefilled syringe (PFS) for self-injection in gMG and CIDP." https://www.sec.gov/Archives/edgar/data/1704292/000162828025023411/zlab-20250331.htm
- SEC Form 10-K (accession 0001704292-26-000015): "In April 2025, our partner argenx announced that the FDA had approved VYVGART Hytrulo pre-filled syringe for self-injection in gMG and CIDP." https://www.sec.gov/Archives/edgar/data/1704292/000170429226000015/zlab-20251231.htm

### April 10, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "This vision has already started to take shape as we continue to innovate on the patient experience with our pre- filled syringe (VYVGART SC) (with an expected Prescription Drug User Fee Act target action date (PDUFA Date) of April 10, 2025) and the auto-injector approval expected in 2027." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "We look forward to continued commercial execution as we expand our patient reach through label enabling studies in seronegative gMG and ocular MG patient populations and we continue to innovate on the patient experience with our pre-filled syringe (PFS) with VYVGART SC, with an PDUFA Date of April 10, 2025." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-033857): "SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) approved a new option for patients to self-inject VYVGART®" https://www.sec.gov/Archives/edgar/data/1697862/000110465925033857/tm2511923d1_ex99-1.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 4.
- First seen 2025-01-13, last confirmed 2025-07-31.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000006): "(4) ongoing proof-of-concept studies in LN, SSc, and AMR, with topline results expected in fourth quarter of 2025, second half of 2026, and 2027, respectively" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "Topline results expected 2H 2025." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- SEC Form 10-K (accession 0001697862-25-000024): "Topline results expected 2H 2025." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000024/argx-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000042): "Japan and Canada by end of 2025, (2) topline results for seronegative gMG (ADAPT-SERON) expected in second half of 2025 and for ocular and pediatric MG (ADAPT-OCULUS, JR) expected in first half of 2026, (3) topline results for ADVANCE-NEXT to support FDA submission of VYVGART IV for primary ITP expected in second half of 2026, (4)" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/argx-20250630_d2.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000042): "UplightTED studies expected in second half of 2026 and (c) registrational UNITY study expected in 2027, (5) proof-of- studies ongoing in LN, SSc and AMR, with topline results expected in fourth quarter of 2025, second half of 2026 and" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/argx-20250630_d2.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000042): "•Proof-of-concept studies ongoing in lupus nephritis (LN), systemic sclerosis (SSc) and antibody mediated rejection (AMR); topline results expected for LN in fourth quarter of 2025, SSc in second half of 2026, and AMR in 2027" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/a04earningspressreleasehy.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000028): "•Proof-of-concept studies ongoing in lupus nephritis (LN), systemic sclerosis (SSc) and antibody mediated rejection (AMR); topline results expected for LN in fourth quarter of 2025, SSc in second half of 2026, and AMR in 2027" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000006): "•Proof-of-concept studies ongoing in lupus nephritis (LN), systemic sclerosis (SSc) and antibody mediated rejection (AMR); topline results expected in LN in fourth quarter of 2025, SSc in second half of 2026, and AMR in 2027" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-002791): "Proof of concept studies ongoing in lupus nephritis (LN), systemic sclerosis (SSc) and antibody mediated rejection (AMR); topline results expected in LN in fourth quarter of 2025, SSc in second half of 2026, and AMR in 2027" https://www.sec.gov/Archives/edgar/data/1697862/000110465925002791/tm253121d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000042): "◦Topline results expected in second half of 2025 for seronegative gMG (ADAPT-SERON) and first half of 2026 for ocular MG (ADAPT OCULUS)" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/a04earningspressreleasehy.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000042): "-Topline results expected in second half of 2025 for seronegative gMG (ADAPT-SERON) and first half of" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/argx-20250630_d2.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000028): "◦Topline results expected in second half of 2025 for seronegative gMG (ADAPT-SERON) and first half of 2026 for ocular and pediatric MG (ADAPT-OCULUS, JR)" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm

### Jan 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: with Seronegative gMG.
- First seen 2026-03-19, last confirmed 2026-03-19.
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000030): "In January 2026, the FDA has accepted for priority review a supplemental BLA for VYVGART for the treatment of adults with Seronegative gMG." https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-03-20, last confirmed 2025-10-30.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000059): "the advancement of anticipated clinical development, data readouts and regulatory milestones and plans, including: (1) the PFS decision on approval expected in Canada by end of 2025, (2) the filing of the sBLA for VYVGART in three AChR-Ab seronegative gMG subtypes by year-end 2025, (3) its pursuit of label expansion through ongoing registrational studies, with topline results expected in first half of 2026 for ocular MG and second half of 2026 for primary ITP" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000059/a02earningspressreleaseq3.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "Topline results expected 1H 2026. argenx Annual Report 2024 2024 In Brief 14 efgartigimod" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- SEC Form 10-K (accession 0001697862-25-000024): "Topline results expected 1H 2026." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000024/argx-20241231.htm

### Feb 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2026-05-11, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001159036-26-000067): "•In February 2026, argenx announced positive topline results from the Phase 3 ADAPT oculus trial of VYVGART® with ENHANZE® in ocular myasthenia gravis." https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/ex991q120268-k.htm
- SEC Form 10-Q (accession 0001159036-26-000145): "In February 2026, argenx announced positive topline results from the Phase 3 ADAPT oculus trial of VYVGART in ocular myasthenia gravis." https://www.sec.gov/Archives/edgar/data/1159036/000115903626000145/halo-20260930.htm
- SEC Form 10-Q (accession 0001159036-26-000104): "In February 2026, argenx announced positive topline results from the Phase 3 ADAPT oculus trial of VYVGART in ocular myasthenia gravis." https://www.sec.gov/Archives/edgar/data/1159036/000115903626000104/halo-20260630.htm
- SEC Form 10-Q (accession 0001159036-26-000068): "In February 2026, argenx announced positive topline results from the Phase 3 ADAPT oculus trial of VYVGART in ocular myasthenia gravis." https://www.sec.gov/Archives/edgar/data/1159036/000115903626000068/halo-20260331.htm
- SEC Form 10-Q (accession 0001159036-26-000068): "•In February 2026, argenx announced positive topline results from the Phase 3 ADAPT oculus trial of VYVGART in ocular myasthenia gravis." https://www.sec.gov/Archives/edgar/data/1159036/000115903626000068/halo-20260331.htm

### March 11, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Primary Immune Thrombocytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04225156 (A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-11 (ACTUAL); Lead Sponsor argenx." https://clinicaltrials.gov/study/NCT04225156

### May 10, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-01-13, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000030): "These data support our supplemental regulatory submission to expand VYVGART into the seronegative population, which was accpeted for priority review with an expected PDUFA target action date of May 10, 2026." https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000010): "VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti-AChR antibody-negative ("seronegative") gMG" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000010/a09earningspressreleaseq4.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-031739): "•Prescription Drug User Fee Act (PDUFA) target action date for anti-acetylcholine receptor antibody negative (AChR-Ab-) gMG (MuSK+, LRP4+ and triple seronegative) is May 10, 2026" https://www.sec.gov/Archives/edgar/data/1697862/000162828026031739/a02earningspressreleaseq1.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-031739): "the Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026 for anti-acetylcholine receptor antibody negative (AChR-Ab-) gMG (MuSK+, LRP4+ and triple seronegative)" https://www.sec.gov/Archives/edgar/data/1697862/000162828026031739/a02earningspressreleaseq1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-045083): "A sBLA for this patient population has been granted priority review by the FDA with a target action date of May 10, 2026." https://www.sec.gov/Archives/edgar/data/1697862/000110465926045083/tm2612048d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000030): "The application has been granted an expected PDUFA date of May 10, 2026." https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000010): "•Prescription Drug User Fee Act (PDUFA) target action date for anti-acetylcholine receptor antibody negative (AChR-Ab-) gMG (MuSK+, LRP4+ and triple seronegative) is May 10, 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000010/a09earningspressreleaseq4.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-003037): "The application has been granted a Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026." https://www.sec.gov/Archives/edgar/data/1697862/000110465926003037/tm262983d1_ex99-1.htm
- SEC Form 10-K (accession 0001697862-26-000032): "The application has been granted an expected PDUFA date of May 10, 2026." https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm

### Jun 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 1. Indication: myasthenia gravis.
- First seen 2026-08-05, last confirmed 2026-11-09.
- SEC Form 10-Q (accession 0001628280-26-072257): "•In June 2026, we announced positive topline data from an ongoing Phase 1 clinical trial evaluating subcutaneous BRIUMVI in patients with AChR-antibody-positive MG and the initiation of a Phase 2 clinical trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG." https://www.sec.gov/Archives/edgar/data/1001316/000162828026072257/tgtx-20260930.htm
- SEC Form 10-Q (accession 0001437749-26-025955): "In June 2026, we announced positive topline data from our Phase 1 clinical trial for BRIUMVI in patients with myasthenia gravis (MG) and the initiation of a Phase 2 clinical trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG." https://www.sec.gov/Archives/edgar/data/1001316/000143774926025955/tgtx20260630_10q.htm

### Q3 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-01-13, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000006): "its plans to develop efgartigimod, including: (1) the ongoing registrational ALKIVIA study evaluating IMNM, ASyS, and DM, with topline results expected in second half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000006): "•Registrational ALKIVIA study ongoing evaluating three myositis subsets (immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM)); topline results expected in second half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000006): "(2) two ongoing registrational UplighTED studies in TED, with topline results expected in second half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-002791): "Registrational ALKIVIA study ongoing evaluating three myositis subsets (immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM); topline results expected in second half of 2026" https://www.sec.gov/Archives/edgar/data/1697862/000110465925002791/tm253121d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000033): "Registrational autoimmune myositis study readout on track for 3Q26, marking a key milestone for VYVGART expansion into rheumatology" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000033/a04earningspressreleasehy.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000030): "Topline results expected in the third quarter of 2026 from ALKIVIA clinical trial evaluating three myositis subsetsIMNM,ASyS and DM with efgartigimod" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "ITP (ADVANCE-NXT): confirmatory clinical trial in ITP ongoing with efgartigimod IV in the U.S. Topline results expected in 2H 2026." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- SEC Form 10-K (accession 0001697862-26-000032): "•Topline results expected in the third quarter of 2026 from ALKIVIA clinical trial evaluating three myositis subsetsIMNM,ASyS and DM with efgartigimod" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm
- SEC Form 10-K (accession 0001697862-25-000024): "•ITP (ADVANCE-NXT): confirmatory clinical trial in ITP ongoing with efgartigimod IV in the U.S. Topline results expected in 2H 2026." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000024/argx-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "Topline results expected 2H 2026." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "Topline results expected in 2H 2026." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- SEC Form 10-K (accession 0001697862-25-000024): "Topline results expected 2H 2026." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000024/argx-20241231.htm

### Q3 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-02-26, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-020017): "argenx's vision of delivering a targeted, transformative treatment option to as many MG patients as possible; its expectation that it will submit a Supplemental Biologics License Application (sBLA) for VYVGART for oMG to the U.S. FDA by end of third quarter 2026;" https://www.sec.gov/Archives/edgar/data/1697862/000110465926020017/tm267379d1_ex99-1.htm

### Aug 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: autoimmune myositis.
- First seen 2026-11-05, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001628280-26-070521): "•Efgartigimod (FcRn): In August 2026, we and our partner argenx announced positive topline results from the Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis." https://www.sec.gov/Archives/edgar/data/1704292/000162828026070521/zlab-20260930.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-03-19, last confirmed 2026-03-19.
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000030): "Topline results expected in the fourth quarter of 2026 for primary ITP (ADVANCE-NEXT) with efgartigimod" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm
- SEC Form 10-K (accession 0001697862-26-000032): "•Topline results expected in the fourth quarter of 2026 for primary ITP (ADVANCE-NEXT) with efgartigimod" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000030): "ADVANCE-NEXT remains ongoing, with topline Phase 3 results expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm
- SEC Form 10-K (accession 0001697862-26-000032): "ADVANCE-NEXT remains ongoing, with topline Phase 3 results expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm

### Feb 2027: PDUFA date

- Status: scheduled. Date confidence: month.
- First seen 2026-10-22, last confirmed 2026-10-22.
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000034): "•sBLA for VYVGART and VYVGART Hytrulo in pediatric gMG accepted for priority review by the FDA, with a PDUFA target action date in February 2027" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a02earningspressreleaseq3.htm

### 2H 2027: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-02-27, last confirmed 2026-06-03.
- Press release filed with the SEC (EX-99) (accession 0001697862-26-000030): "Topline results from UNITY clinical trial (SjD) expected in second half of 2027 with efgartigimod" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm
- SEC Form 10-K (accession 0001697862-26-000032): "•Topline results from UNITY clinical trial (SjD) expected in second half of 2027 with efgartigimod" https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-069786): "Topline results are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1697862/000110465926069786/tm2616678d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "Topline results expected in 2027." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- SEC Form 10-K (accession 0001697862-25-000024): "Topline results expected in 2027." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000024/argx-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000006): "(3) Registrational UNITY study in primary Sjögren's disease, with topline results expected in 2027" https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm

## Same indication

- [Vyvgart (efgartigimod alfa)](https://sec-api.dev/pdufa/efgartigimod-alfa) (ARGX)
- [Efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) (ARGX)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [PF-06835375](https://sec-api.dev/pdufa/pf-06835375) (PFE)
- [Povetacicept](https://sec-api.dev/pdufa/povetacicept) (VRTX)
- [Nplate (romiplostim)](https://sec-api.dev/pdufa/romiplostim) (AMGN)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)

Calendar months: [May 2026](https://sec-api.dev/fda-calendar/2026-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/efgartigimod.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VYVGART (efgartigimod) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/efgartigimod

```bibtex
@misc{secapidev_pdufa_efgartigimod_20261116,
  title        = {VYVGART (efgartigimod) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/efgartigimod}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_efgartigimod_20261116","title":"VYVGART (efgartigimod) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/efgartigimod","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
